Merck & Co., Inc. (MRK) to Present New Data for VICTRELIS® (boceprevir) and MK-5172 at the American Association for Study of Liver Diseases 2012 Annual Meeting  
10/1/2012 10:34:48 AM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from Phase III studies of VICTRELIS® (boceprevir) 200 mg Capsules, the company’s oral hepatitis C virus (HCV) NS3/4A protease inhibitor will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). The meeting will take place November 9-13 in Boston.